Can Fite Bio (CANF) AI Stock Analysis

• Market Cap: 47.80M
• Dividend Yield: N/A
• Average Volume (3M): 7.40M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.35
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: IL
• Employees: 5
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 3,983,400,600
• 10 Day Avg. Volume: 10,154,301
• 30 Day Avg. Volume: 7,396,868
• PEG Ratio: 0.06
• Price to Book (P/B): 3.80
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.86
• Enterprise Value/Market Cap: 0.14
• Enterprise Value/Revenue: 2.13
• Enterprise Value/Gross Profit: 8.97
• Enterprise Value/Ebitda: -0.17
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 42 Neutral
• Price Target: 1.00 ▼(-47.37%Downside)

Can Fite Bio's overall stock score is primarily impacted by its poor financial performance and negative technical trends. The lack of valuation metrics further compounds the challenges, highlighting the company's struggles with profitability and market presence. Without positive earnings guidance or corporate events, the outlook remains weak.

Can Fite Bio Business Overview & Revenue Model

Company Description

Can Fite BioPharma Ltd. (CANF) is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics for the treatment of autoimmune-inflammatory, oncological, and liver diseases. Headquartered in Israel, the company leverages its proprietary technology platforms to develop pharmaceutical drugs that target specific pathways associated with these diseases, offering potential solutions for unmet medical needs. Key products in Can Fite's pipeline include Piclidenoson for rheumatoid arthritis and psoriasis, Namodenoson for liver cancer and NAFLD/NASH, and CF602 for treating sexual dysfunction.

How the Company Makes Money

Can Fite BioPharma generates revenue primarily through licensing agreements, milestone payments, and royalties from partnerships with other pharmaceutical and biotechnology companies. These partnerships often involve the out-licensing of Can Fite's drug candidates to partners who then undertake further development, manufacturing, and commercialization. The company earns milestone payments as the drug candidates progress through various stages of clinical trials and regulatory approvals. Additionally, once a partnered drug is commercialized, Can Fite receives royalties on product sales. The company may also engage in grant funding for specific research projects, which contributes to its revenue stream.

Can Fite Bio Financial Statement Overview

Summary

Can Fite Bio faces declining revenues and significant profitability challenges, with deeply negative EBIT, EBITDA, and net profit margins. Despite low leverage, the declining equity efficiency and negative cash flow indicate substantial financial strain.

Income Statement

Can Fite Bio has been experiencing declining revenues, with a 9.28% decrease from 2023 to 2024. Despite maintaining a 100% gross profit margin due to negligible cost of goods sold, the company faces significant challenges with profitability, as indicated by a negative net profit margin of -1169.58% in 2024. The EBIT and EBITDA margins are deeply negative, reflecting ongoing operational losses. Overall, the income statement indicates substantial financial strain with limited revenue growth.

Balance Sheet

The company maintains a reasonable debt-to-equity ratio of 0.02, indicating low leverage. However, the equity ratio decreased from 2023 to 2024, standing at 59.62%, suggesting a decline in financial stability. The return on equity is significantly negative at -145.01%, highlighting unprofitability for shareholders. Despite low debt levels, the company's balance sheet reflects challenges in improving equity returns and asset efficiency.

Cash Flow

Can Fite Bio's cash flow remains under pressure with a negative free cash flow of -$7.64 million in 2024. The operating cash flow to net income ratio is 0.97, indicating cash losses align with net losses. Despite a free cash flow improvement from the previous year by 9.47%, the company struggles to generate positive cash flow, reflecting ongoing operational inefficiencies and cash management challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	743.00K	674.00K	743.00K	810.00K	853.00K	763.00K
Gross Profit	743.00K	674.00K	743.00K	810.00K	853.00K	763.00K
EBITDA	-8.18M	-8.12M	-8.18M	-10.08M	-12.83M	-14.13M
Net Income	-7.47M	-7.88M	-7.63M	-10.53M	-12.60M	-14.81M
Balance Sheet
Total Assets	9.99M	9.12M	9.99M	9.28M	20.25M	9.52M
Cash, Cash Equivalents and Short-Term Investments	8.92M	7.89M	8.92M	7.98M	19.14M	8.34M
Total Debt	40.00K	104.00K	40.00K	62.00K	124.00K	67.00K
Total Liabilities	3.75M	3.68M	3.75M	4.81M	5.87M	3.45M
Stockholders Equity	6.24M	5.44M	6.24M	4.47M	14.38M	6.07M
Cash Flow
Free Cash Flow	0.00	-7.64M	-8.44M	-10.81M	-9.87M	-12.09M
Operating Cash Flow	0.00	-7.64M	-8.44M	-10.80M	-9.86M	-12.06M
Investing Cash Flow	0.00	1.50M	498.00K	9.50M	-14.51M	-26.00K
Financing Cash Flow	0.00	6.71M	9.14M	0.00	20.46M	17.68M

Can Fite Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:CANF, the sentiment is Negative. The current price of 1.9 is above the 20-day moving average (MA) of 1.33, above the 50-day MA of 1.39, and below the 200-day MA of 2.03, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 46.15 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:CANF.

Can Fite Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BLRX	51 Neutral	66.50M	―		―	90.65%	90.80%
Sector *	46 Neutral	C$194.85M	-4.28	-8.56%	2.84%	13.52%	-1.74%
CANF	42 Neutral	47.80M	―		―	―	―

Can Fite Bio Corporate Events

Can-Fite’s Namodenoson Shows Promise in Treating Liver Cirrhosis

Can-Fite BioPharma Ltd. announced a significant clinical development with its drug Namodenoson, which successfully eliminated episodes of decompensated liver cirrhosis in a patient under a compassionate use program. The treatment led to significant symptom improvements and the potential for Namodenoson to provide a therapeutic option for patients awaiting liver transplants. This development addresses a critical need in the liver cirrhosis treatment market, projected to reach $15 billion in the U.S. by 2030, potentially positioning Can-Fite as a key player in this sector.

Can Fite Bio Nears Completion of Subsidiary Share Acquisition

Can Fite Bio has reached an agreement on significant terms for the acquisition of its subsidiary’s shares by a private investor, with the finalization expected soon. The acquisition marks a strategic development for the company, as it previously announced the purchase and has now completed the acquisition successfully, indicating potential positive impacts on its market positioning.